Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1UG3HL157401-01A1 | U.S. NIH Grant/Contract | View source | |
| 1U24HL157310-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| The University of Texas Health Science Center, Houston | OTHER |
Not provided
Not provided
Not provided
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.
The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.
The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LTOWB | Active Comparator | Participants randomized to receive (Low Titer O Whole Blood [LTOWB]) |
|
| Components | Active Comparator | Participants randomized to receive the component blood products. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LTOWB | Biological | Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| 6-hour Mortality | Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant) | First 6 hours after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| 24-hour Mortality | Participant vital status at 24-hours following randomization | First 24 hours after randomization |
| Hospital/30-day Mortality | Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier) |
Not provided
Inclusion Criteria:
Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)
Patient taken to trauma center directly from scene
Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting
Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol
Traumatic injury with at least one of the following:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shannon Stephens, EMTP, CCEMTP | Contact | 205-934-5890 | swstephens@uabmc.edu | |
| Kiran Mansoor, MBBS | Contact | 713-500-9643 | Kiran.Mansoor@uth.tmc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Jan Jansen, MBBS, PhD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham, UAB Hospital | Recruiting | Birmingham | Alabama | 35294 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40753420 | Derived | Jansen JO, Pedroza C, Novelo LL, Hao T, DeWildt GR, Coton CF, Mansoor K, Stephens SW, Marques MB, Stubbs JR, Richter JR, Wang HE, Holcomb JB, DeSantis SM. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y. | |
| 38531812 | Derived | Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27. |
| Label | URL |
|---|---|
| TROOP Consortium website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Care providers will be blinded to assignment until the point of randomization, which is when the cooler is opened, in the trauma bay, to remove blood products for transfusion.
| Components | Biological | Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously. |
|
| From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Incidence of Pre-specified Complications | The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Adjudicated Primary Cause of Death | Primary cause of death as reviewed and determined by the study investigators (consensus) | 30-days post randomization |
| Length of Stay (Hospital and Intensive Care Unit) | Number of hours hospitalized (includes both hospital and intensive care unit time) | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Hospital-, Ventilator- and Intensive Care Unit-free days | Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit. | 30-days post randomization |
| Incidence of major surgical procedures | The proportion of participants undergoing major surgical procedures. | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Time to hemostasis in those undergoing procedures with a hemostatic component | Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival. | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization | The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.) | First 24 hours after randomization |
| Discharge destination | Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc. | At hospital discharge or 30-days post randomization (whichever the earlier) |
| Functional status | Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome. | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Patient's quality of life | Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome. | From randomization to hospital discharge or 30-days post randomization (whichever the earlier) |
| Los Angeles County + University of Southern California (LAC + USC) Medical Center | Not yet recruiting | Los Angeles | California | 90033 | United States |
| University Medical Center New Orleans LCMC Health | Not yet recruiting | New Orleans | Louisiana | 70112 | United States |
| University of Maryland Medical Center | Not yet recruiting | Baltimore | Maryland | 21201 | United States |
| Washington University School of Medicine | Not yet recruiting | St Louis | Missouri | 63110 | United States |
| Atrium Health Wake Forest Baptist | Not yet recruiting | Winston-Salem | North Carolina | 27157 | United States |
| University of Cincinnati Medical Center | Recruiting | Cincinnati | Ohio | 45267 | United States |
|
| Oregon Health and Sciences University Hospital | Not yet recruiting | Portland | Oregon | 97239 | United States |
| Penn Presbyterian Medical Center | Not yet recruiting | Philadelphia | Pennsylvania | 19104 | United States |
| University of Texas Health Science Center Houston | Not yet recruiting | Houston | Texas | 77030 | United States |
| University of Texas Health San Antonio and University Health System | Not yet recruiting | San Antonio | Texas | 78229 | United States |
| Harborview Medical Center | Recruiting | Seattle | Washington | 98104 | United States |
|
| Froedtert Hospital | Not yet recruiting | Milwaukee | Wisconsin | 53226 | United States |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
| D012771 | Shock, Hemorrhagic |
| D012769 | Shock |
| D006470 | Hemorrhage |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004602 | Elements |
| ID | Term |
|---|---|
| D007287 | Inorganic Chemicals |
Not provided
Not provided